Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: The evidence to date

Drug Design, Development and Therapy

Volumn 10, Issue , 2016, Pages 2387-2399

  Ebstie, Yehenew A ^a   Abay, Solomon M ^a   Tadesse, Wondmagegn T ^b   Ejigu, Dawit A ^c  

^a Immunology and Parasitology ^*  (Ethiopia)

^b ADDIS ABABA UNIVERSITY   (Ethiopia)

^c ST PAUL S HOSPITAL MILLENNIUM MEDICAL COLLEGE   (Ethiopia)

Author keywords

Hypnozoite; Primaquine; Radical cure; Schizonts; Vivax malaria

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; CHLOROQUINE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HEMOGLOBIN; METHEMOGLOBIN; PRIMAQUINE; TAFENOQUINE; AMINOQUINOLINE DERIVATIVE; ANTIMALARIAL AGENT;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; CHEMOPROPHYLAXIS; CORNEA DISEASE; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DYSENTERY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOLYSIS; HUMAN; KERATOPATHY; LEUKOCYTE COUNT; MALARIA CONTROL; META ANALYSIS (TOPIC); METHEMOGLOBINEMIA; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMODIUM VIVAX MALARIA; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTE COUNT; TREATMENT OUTCOME; VECTOR CONTROL; DRUG EFFECTS; MALARIA, VIVAX; MICROBIOLOGY; PLASMODIUM VIVAX;

AMINOQUINOLINES; ANTIMALARIALS; HUMANS; MALARIA, VIVAX; PLASMODIUM VIVAX;

EID: 84983350354     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S61443     Document Type: Review

References (99)

1. World Health Organization. World Malaria Report 2015. Geneva: World Health Organization; 2015.
2. World Health Organization. World Malaria Report 2014. Vol. 55. Geneva: World Health Organization; 2014.
3. World Health Organization. Global Technical Strategy for Malaria 2016–2030. Geneva: World Health Organization; 2015.
4. Battle KE, Gething PW, Elyazar IRF, et al. The Global Public Health Significance of Plasmodium Vivax. Vol. 80. Amsterdam: Elsevier; 2012.
5. Naing C, Whittaker MA, Nyunt Wai V, Mak JW. Is Plasmodium vivax malaria a severe malaria?: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2014;8(8):e3071.
6. Carlton JM, Adams JH, Silva JC, et al. Comparative genomics of the neglected human malaria parasite Plasmodium vivax. Nature. 2008;455(7214):757–763.
7. Baird JK. Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev. 2009;22(3):508–534.
8. Popovici J, Ménard D. Challenges in antimalarial drug treatment for vivax malaria control. Trends Mol Med. 2015;21(12):776–788.
9. Price RN, Tjitra E, Guerra CA, et al; UKPMC Funders Group. Vivax malaria: neglected and not benign. Am J Trop Med Hyg. 2007;77(6):79–87.
10. Bhardwaj M, Bharadwaj L, Trigunayat K, Trigunayat MM. Thermal characterization of Plasmodium falciparum species specific proteins in Indian geographical area. Nat Preced. 2010. Available from: http://precedings.nature.com/documents/4565/version/1. Accessed July 28, 2016.
11. Lacerda MV, Mourão MP, Alexandre MA, et al. Understanding the clinical spectrum of complicated Plasmodium vivax malaria: a systematic review on the contributions of the Brazilian literature. Malar J. 2012;11:12.
12. Guerin PJ, Olliaro P, Nosten F, et al. Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect Dis. 2002;2(9):564–573.
13. Flannery EL, Chatterjee AK, Winzeler EA. Antimalarial drug discovery–approaches and progress towards new medicines. Nat Rev Microbiol. 2013;11(12):849–862.
14. Kheng S, Muth S, Taylor WR, et al. Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiency. BMC Med. 2015;13(1):1–10.
15. Val FF, Sampaio VS, Cassera MB, et al. Plasmodium vivax malaria elimination: should innovative ideas from the past be revisited? Mem Inst Oswaldo Cruz. 2014;109(5):522–524.
16. Collins WE, Jeffery GM. Primaquine resistance in Plasmodium vivax. Am J Trop Med Hyg. 1996;55(3):243–249.
17. Cowman AF, Berry D, Baum J. The cellular and molecular basis for malaria parasite invasion of the human red blood cell. J Cell Biol. 2012;198(6):961–971.
18. White MT, Karl S, Battle KE, Hay SI, Mueller I, Ghani AC. Modelling the contribution of the hypnozoite reservoir to Plasmodium vivax transmission. Elife. 2014;3:e04692.
19. White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J. 2011;10(1):297.
20. Velho DP, Alves-jr ER, Ribatski-silva D, Gomes LT. Factors associated with recurrent Plasmodium vivax malaria in Porto Velho, Rondônia State, Brazil. Cad Saude Publica. 2014;30(7):1403–1417.
21. Chen N, Auliff A, Rieckmann K, Gatton M, Cheng Q. Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals. J Infect Dis. 2007;195(7):934–941.
22. Pindolia DK, Garcia AJ, Huang Z, et al. The demographics of human and malaria movement and migration patterns in East Africa. Malar J. 2013;12:397.
23. World Health Organization. Control and Elimination of Plasmodium vivax Malaria: A Technical Brief. Vol. 17. Geneva: World Health Organization; 2015.
24. RTS S Clinical Trials Partnership. Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomized, controlled trial. Lancet. 2015;386(9988):31–45.
25. World Health Organization. Reversing the Incidence of Malaria 2000–2015. Geneva: World Health Organization; 2015.
26. United Nations. The Millennium Development Goals Report 2014. New York: United Nations; 2014.
27. Aregawi M, Lynch M, Bekele W, et al. Time series analysis of trends in malaria cases and deaths at hospitals and the effect of antimalarial interventions, 2001–2011, Ethiopia. PLoS One. 2014;9(11):e106359.
28. Roll Back Malaria Partnership. World Malaria Day–Asia, April 2014. Geneva: Roll Back Malaria Partnership; 2015.
29. Karema C, Aregawi MW, Rukundo A, et al. Trends in malaria cases, hospital admissions and deaths following scale-up of anti-malarial interventions, 2000–2010, Rwanda. Malar J. 2012;11:236.
30. Masaninga F, Chanda E, Chanda-kapata P, et al. Review of the malaria epidemiology and trends in Zambia. Asian Pac J Trop Biomed. 2013;3(2):89–94.
31. World Health Organization. Malaria: Global Fund Proposal Development. Geneva: World Health Organization; 2011:1–20.
32. Ukpe IS, Moonasar D, Raman J, Barnes KI, Baker L, Blumberg L. Case management of malaria: treatment and chemoprophylaxis. S Afr Med J. 2014;103(10):793–798.
33. Wilson ML. Laboratory diagnosis of malaria: conventional and rapid diagnostic methods. Arch Pathol Lab Med. 2013;137(6):805–811.
34. World Health Organization. Parasitological Confirmation of Malaria Diagnosis. Geneva: World Health Organization; 2009.
35. World Health Organization. Universal Access to Malaria Diagnostic Testing: An Operational Manual. Vol. 12. Geneva: World Health Organization; 2013.
36. Battle KE, Karhunen MS, Bhatt S, et al. Geographical variation in Plasmodium vivax relapse. Malar J. 2014;13(1):144.
37. World Health Organization. Guidelines for the Treatment of Malaria. 2nd ed. Geneva: World Health Organization; 2010.
38. Eibach D, Ceron N, Krishnalall K, et al. Therapeutic efficacy of artemether-lumefantrine for Plasmodium vivax infections in a prospective study in Guyana. Malar J. 2012;11:347.
39. Naing C, Aung K, Win DK, Wah MJ. Efficacy and safety of chloroquine for treatment in patients with uncomplicated Plasmodium vivax infections in endemic countries. Trans R Soc Trop Med Hyg. 2010;104(11):695–705.
40. World Health Organization. Guidelines for the Treatment of Malaria. 3rd ed. Geneva: World Health Organization; 2015.
41. Imwong M, Snounou G, Pukrittayakamee S, et al. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis. 2007;195(7):927–933.
42. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN. Europe PMC Funders Group artemisinin combination therapy for vivax malaria? Lancet Infect Dis. 2012;10(6):405–416.
43. Mekonnen SK, Aseffa A, Medhin G, Berhe N, Velavan TP. Re-evaluation of microscopy confirmed Plasmodium falciparum and Plasmodium vivax malaria by nested PCR detection in southern Ethiopia. Malar J. 2014;13(1):48.
44. Senn H, Alattas N, Boggild AK, Morris SK. Mixed-species Plasmodium falciparum and Plasmodium ovale malaria in a paediatric returned traveller. Malar J. 2014;13(1):78.
45. Zakeri S, Kakar Q, Ghasemi F, et al. Detection of mixed Plasmodium falciparum & Plasmodium vivax infections by nested-PCR in Pakistan, Iran & Afghanistan. Indian J Med Res. 2010;132:31–35.
46. Nicholas DM, John GK, von Seidlein L, Nicholas AM, Ric PN. Chemotherapeutic Strategies for Reducing Transmission of Plasmodium vivax Malaria. Vol. 80. Amsterdam: Elsevier; 2012.
47. Rahimi BA, Thakkinstian A, White NJ, Sirivichayakul C, Dondorp AM, Chokejindachai W. Severe vivax malaria: a systematic review and meta-analysis of clinical studies since 1900. Malar J. 2014;13(1):1–10.
48. Pasvol G. The treatment of complicated and severe malaria. Br Med Bull. 2006;75–76(1):29–47.
49. Baird JK, Schwartz E, Hoffman SL. Prevention and treatment of vivax malaria. Curr Infect Dis Rep. 2007;9(1):39–46.
50. Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg. 2006;75(3):402–415.
51. Hobbs C, Duffy P. Drugs for malaria: something old, something new, something borrowed. F1000 Biol Rep. 2011;3:24.
52. Vale N, Moreira R, Gomes P. Primaquine revisited six decades after its discovery. Eur J Med Chem. 2009;44(3):937–953.
53. Baird JK. Suppressive chemoprophylaxis invites avoidable risk of serious illness caused by Plasmodium vivax malaria. Travel Med Infect Dis. 2013;11(1):60–65.
54. Baird JK, Fryauff DJ, Hoffman SL. Primaquine for prevention of malaria in travelers. Clin Infect Dis. 2003;37(12):1659–1667.
55. John GK, Douglas NM, von Seidlein L, et al. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J. 2012;11(1):280.
56. Campo B, Vandal O, Wesche DL, Burrows JN. Killing the hypnozoite–drug discovery approaches to prevent relapse in Plasmodium vivax. Pathog Glob Health. 2015;109(3):107–122.
57. Fernando D, Rodrigo C, Rajapakse S. Primaquine in vivax malaria: an update and review on management issues. Malar J. 2011;10(1):351.
58. Beutler E, Duparc S; G6PD Deficiency Working Group. Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg. 2007;77(4):779–789.
59. Carter N, Pamba A, Duparc S, Waitumbi JN. Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials. Malar J. 2011;10(1):241.
60. Howes RE, Piel FB, Patil AP, et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med. 2012;9(11):e1001339.
61. Buchachart K, Krudsood S, Singhasivanon P, et al. Effect of primaquine standard dose (15 mg/day for 14 days) in the treatment of vivax malaria patients in Thailand. Southeast Asian J Trop Med Public Health. 2001;32(4):720–726.
62. Ramos Júnior WM, Sardinha JF, Costa MR, Santana MS, Alecrim MG, Lacerda MV. Clinical aspects of hemolysis in patients with Plasmodium vivax malaria treated with primaquine, in the Brazilian Amazon. Braz J Infect Dis. 2010;14(4):410–412.
63. World Health Organization. The Safety and Effectiveness of Single Dose Primaquine as a Plasmodium falciparum Gametocytocide. Geneva: World Health Organization; 2012:1–19.
64. Coleman M, Coleman N. Drug-induced methaemoglobinaemia. Treatment issues. Drug Saf. 1996;14(6):394–405.
65. Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis. 2004;39(9):1336–1345.
66. Bunnag D, Karbwang J, Thanavibul A, et al. High dose of primaquine in primaquine resistant vivax malaria. Trans R Soc Trop Med Hyg. 1994;88(2):218–219.
67. Jelinek T, Nothdurft HD, Von Sonnenburg F, Loscher T. Long-term efficacy of primaquine in the treatment of vivax malaria in nonimmune travelers. Am J Trop Med Hyg. 1995;52(4):322–324.
68. GlaxoSmithKline [webpage on the Internet]. GSK and MMV Announce Start of Phase III Programme of Tafenoquine for Plasmodium vivax Malaria. 2014:1–3. Available from: https://us.gsk.com/en-us/media/press-releases/2014/gsk-and-mmv-announce-start-of-phase-iii-programme-of-tafenoquine-for-plasmodium-vivax-malaria/. Accessed July 28, 2016.
69. Brueckner RP, Lasseter KC, Lin ET, Schuster BG. First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial. Am J Trop Med Hyg. 1998;58(5):645–649.
70. Green JA, Patel AK, Patel BR, et al. Tafenoquine at therapeutic concentrations does not prolong fridericia-corrected QT interval in healthy subjects. J Clin Pharmacol. 2014;54(9):995–1005.
71. Edstein MD, Kocisko DA, Walsh DS, Eamsila C, Charles BG, Rieckmann KH. Plasma concentrations of tafenoquine, a new long-acting antimalarial agent, in Thai soldiers receiving monthly prophylaxis. Clin Infect Dis. 2003;37(12):1654–1658.
72. Edstein MD, Kocisko DA, Brewer TG, Walsh DS, Eamsila C, Charles BG. Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers. Br J Clin Pharmacol. 2001;52(6):663–670.
73. Edstein MD, Nasveld PE, Kocisko DA, Kitchener SJ, Gatton ML, Rieckmann KH. Gender differences in gastrointestinal disturbances and plasma concentrations of tafenoquine in healthy volunteers after tafenoquine administration for post-exposure vivax malaria prophylaxis. Trans R Soc Trop Med Hyg. 2007;101(3):226–230.
74. Li Q, O’Neil M, Xie L, et al. Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infections. Malar J. 2014;13(1):141.
75. Pybus BS, Marcsisin SR, Jin X, et al. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Malar J. 2013;12(1):212.
76. Marcsisin SR, Sousa JC, Reichard GA, et al. Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds. Malar J. 2014;13(1):2.
77. Vuong C, Xie LH, Potter BB, et al. Differential CYP 2D metabolism alters tafenoquine pharmacokinetics. Antimicrob Agents Chemother. 2015;59(7):3864–3869.
78. Vennerstrom JL, Nuzum EO, Miller RE, et al. 8-Aminoquinolines active against blood stage Plasmodium falciparum in vitro inhibit hematin polymerization. Antimicrob Agents Chemother. 1999;43(3):598–602.
79. Pradines B, Mamfoumbi MM, Tall A, et al. In vitro activity of tafenoquine against the asexual blood stages of Plasmodium falciparum isolates from Gabon, Senegal, and Djibouti. Antimicrob Agents Chemother. 2006;50(9):3225–3226.
80. Ponsa N, Sattabongkot J, Kittayapong P, Eikarat N, Coleman RE. Transmission-blocking activity of tafenoquine (WR-238605) and artelinic acid against naturally circulating strains of Plasmodium vivax in Thailand. Am J Trop Med Hyg. 2003;69(5):542–547.
81. Research Councils UK [webpage on the Internet]. Defining the Mechanism of Action of the 8-Aminoquinolines: A Pre-Requisite to Rationally Designed Safe Antimalarials for the Elimination Era. Available from: http://gtr.rcuk.ac.uk/projects?ref=MR/L000644/1. Accessed April 13, 2016.
82. Malaria Nexus [webpage on the Internet]. Tafenoquine Gets a U.S. Food and Drug Administration (FDA) Breaththrough Therapy Designation. 2014. Available from: http://www.malarianexus.com/news/tafenoquine-gets-u-s-food-and-drug-administration-fda-breakthrough/. Accessed May 23, 2016.
83. Center for Health Policy [webpage on the Internet]. Breakthrough Therapy Designation: Exploring the Qualifying Criteria. 2015. Available from: http://www.brookings.edu/events/2015/04/24-fda-breakthrough-therapy-criteria. Accessed May 23, 2016.
84. Beck HP, Wampfler R, Carter N, et al. Estimation of the antirelapse efficacy of tafenoquine, using Plasmodium vivax genotyping. J Infect Dis. 2016;213(5):794–799.
85. Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet. 2014;383(9922):1049–1058.
86. Walsh DS, Looareesuwan S, Wilairatana P, et al. Randomized dose-ranging study of the safety and efficacy of WR 238605 (tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand. J Infect Dis. 1999;180(4):1282–1287.
87. Walsh DS, Wilairatana P, Tang DB, et al. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Clin Infect Dis. 2004;39(8):1095–1103.
88. Edstein M, Walsh D, Eamsila C, et al. Malaria prophylaxis/radical cure: recent experiences of the Australian Defense Force. Med Trop. 2001;61(1):1–2.
89. Brueckner RP, Coster T, Wesche DL, Shmuklarsky M, Schuster BG. Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial. Antimicrob Agents Chemother. 1998;42(5):1293–1294.
90. Hale BR, Owusu-Agyei S, Fryauff DJ, et al. A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum. Clin Infect Dis. 2003;36(5):541–549.
91. Shanks GD, Oloo AJ, Aleman GM, et al. A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria. Clin Infect Dis. 2001;33(12):1968–1974.
92. Lell B, Faucher JF, Missinou MA, et al. Malaria chemoprophylaxis with tafenoquine: a randomised study. Lancet. 2000;355(9220):2041–2045.
93. Nasveld PE, Edstein MD, Reid M, et al. Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects. Antimicrob Agents Chemother. 2010;54(2):792–798.
94. Elmes NJ, Nasveld PE, Kitchener SJ, Kocisko DA, Edstein MD. The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific. Trans R Soc Trop Med Hyg. 2008;102(11):1095–1101.
95. Nasveld P, Kitchener S, Edstein M, Rieckmann K. Comparison of tafenoquine (WR238605) and primaquine in the post-exposure (terminal) prophylaxis of vivax malaria in Australian Defense Force personnel. Trans R Soc Trop Med Hyg. 2002;96(6):683–684.
96. Nasveld P, Kitchener S. Treatment of acute vivax malaria with tafenoquine. Trans R Soc Trop Med Hyg. 2005;99(1):2–5.
97. Kitchener S, Nasveld P, Edstein MD. Short report: tafenoquine for the treatment of recurrent Plasmodium vivax malaria. Am J Trop Med Hyg. 2007;76(3):494–496.
98. Walsh D, Eamsila C, Sasiprapha T, et al. Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant Plasmodium falciparum malaria. J Infect Dis. 2004;190(8):1456–1463.
99. PubChem [webpage on the Internet]. Primaquine: Compound Summary for CID 4908. 2005. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/primaquine. Accessed May 23, 2016.